samedan logo

home > news > detailed info

Bormioli Pharma runs Envision 2020: A Digital Event to Showcase The New Strategic Directions, Brand-New Product Portfolios and Prototypes

Bormioli Pharma

An opening press briefing with Bormioli Pharma top management is scheduled for the 1st December at 11.00am CET.

The event will be held on a dedicated platform in the first half of December.

Parma, 24 November 2020 – Bormioli Pharma will showcase its brand-new product portfolios, products and prototypes during “Bormioli Pharma Envision 2020”, a digital event that will take place in the first half of December open to all the stakeholders.

The event will be the occasion to get in touch with the leading European pharma packaging manufacturer in glass and plastic in such hectic times for the industry. Even during the Covid-19 pandemic, the company has kept the momentum for its expansion and growth process, finalizing new investments and M&As to enlarge its industrial platform and the products range.

Bormioli Pharma will also present a reorganization of the product portfolio, with a brand-new segmentation of the commercial offer according to the specific target markets.

Moreover, Bormioli Pharma Envision 2020 will also feature the showcase of the new products, addressing emerging needs both in pharma parenteral and oral markets as well as in the nutraceutical one.

Finally, during the event Bormioli Pharma will showcase prototypes addressing some of the growing needs in the pharma industry, including usability, sustainability, connectivity and traceability.

Bormioli Pharma Envision 2020 will be held from 30th November to 11th December on a dedicated platform, and registration to this hyperlink is required.

A special opening session with Andrea Lodetti CEO Bormioli Pharma and Andrea Sentimenti, Marketing & Innovation Director, will be dedicated to the press, with a e-briefing – via Zoom platform – scheduled for the 1st December at 11.00am CET.
phone +390383947611
email Via Tortona 48, 27055 Rivanazzano Terme (PV)
Print this page
Send to a friend
News and Press Releases

Ampio’s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients With Respiratory Distress

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following clearance by the Safety Monitoring Committee (SMC), which found Ampion to be safe and well-tolerated after reviewing results from the first three treatment groups.
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management


Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement